SIK3 (Gene)

Synonyms:ENTREZ:23387, HGNC:29165, L19, MIM:614776, NM_001281748, NM_001281749, NM_001366686, NM_001366687, NM_025164, NP_001268677, NP_001268678, NP_001353615, NP_001353616, NP_079440, QSK, SEMDK, SIK family kinase 3, SIK-3, SIK3, XM_005271482, XM_005271484, XM_005271485, XM_011542722, XM_011542723, XM_011542724, XM_011542725, XM_011542726, XM_017017424, XM_017017425, XM_017017426, XM_017017427, XP_005271539, XP_005271541, XP_005271542, XP_011541024, XP_011541025, XP_011541026, XP_011541027, XP_011541028, XP_016872913, XP_016872914, XP_016872915, XP_016872916, XR_001747816
Omim:OMIM:614776
Id:ENSG00000160584
Hgnc:HGNC:29165
Entrez:23387
Description:SIK family kinase 3
Enables ATP binding activity; magnesium ion binding activity; and protein serine/threonine kinase activity. Involved in positive regulation of TORC1 signaling; positive regulation of TORC2 signaling; and protein phosphorylation. Located in nucleoplasm. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View SIK3's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with SIK3.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using SIK3.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for SIK3.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with SIK3.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.